STOCK TITAN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

Welcome to our dedicated news page for Regeneron Pharmaceuticals (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regeneron Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regeneron Pharmaceuticals's position in the market.

Rhea-AI Summary
Regeneron Pharmaceuticals announces the addition of Kathryn Guarini and David P. Schenkein to its Board of Directors. Guarini brings technology and business experience, while Schenkein has expertise in oncology and hematology. Marc Tessier-Lavigne has retired from the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Regeneron Pharmaceuticals to participate in upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary
Regeneron receives funding from BARDA for clinical development of next-generation COVID-19 monoclonal antibody therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals receives FDA approval for Veopoz for the treatment of CHAPLE disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for odronextamab, an investigational CD20xCD3 bispecific antibody, for the treatment of relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). Odronextamab has received Orphan Drug Designation for FL and DLBCL. The MAA is supported by data from Phase 1 and Phase 2 trials, and Regeneron is conducting a Phase 3 development program to further investigate odronextamab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive, two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (wAMD). The study showed that 88% of patients were on a ≥12-week dosing interval at the end of two years, with 78% maintaining ≥12-week intervals throughout the study period. Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA® (aflibercept) 2 mg Injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals and Decibel Therapeutics have announced a definitive agreement for the acquisition of Decibel by Regeneron. The acquisition will be at a price of $4.00 per share of Decibel common stock, with an additional non-tradeable contingent value right (CVR) of up to $3.50 per share. The proposed acquisition values Decibel at a total equity value of approximately $109 million, and up to approximately $213 million if certain milestones are achieved. Decibel's lead investigational gene therapy, DB-OTO, is currently in its first clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced an 11% increase in Q2 2023 revenues to $3.16 billion, with Dupixent® global net sales up 33% to $2.79 billion. EYLEA® U.S. net sales were $1.50 billion. Q2 2023 GAAP diluted EPS was $8.50 and non-GAAP diluted EPS was $10.24. Aflibercept 8 mg BLA decision is expected in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces winners of the 11th annual Regeneron Prize for Creative Innovation honoring exceptional talent and originality in biomedical research. Winners receive cash prizes to pursue groundbreaking research projects in the field of biomedical science, totaling $140,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

REGN Stock Data

99.30B
102.75M
2.58%
89.25%
1.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Tarrytown

About REGN

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.